Jaguar Health (NASDAQ:JAGX) said its patient enrollment had surpassed 90% for the Phase 3 trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy with or ...

Initial Tranche of Non-dilutive Financing Transaction Increased from $5 Million to $6 Million by Mutual Consent with Lender, Providing Additional Q4 2020 Funding for Pivotal Phase 3 Clinical Trial and ...

Cancer patients at patient advocacy events voice strong support for company's focus on patient quality of life and the highly neglected need for new therapies for cancer therapy-related diarrhea SAN ...

Potential treatment for patients with breast cancer with metastasis to the brain with crofelemer would augment the significant responder analysis results for crofelemer in the prespecified subgroup of ...

Some adults with celiac disease have persistent diarrhea despite compliance with a gluten-free diet. Pancreatic exocrine insufficiency could cause this problem, but it is difficult to diagnose ...

A drug purified and developed from the sap of a tree in the Amazon rainforest is now being studied for the treatment of chronic idiopathic diarrhea in non-HIV patients at The University of Texas ...

March 18 (UPI) --Fever, cough and shortness of breath have been widely acclaimed as the hallmark symptoms of COVID-19, the disease caused by the new coronavirus, but a new analysis suggests diarrhea ...

Stage II completed; comprehensive results expected in Q1 2024; company's planned regulatory pathway for FDA approval remains on track Cancer patients at patient advocacy events voice strong support ...

SAN FRANCISCO, CA / ACCESSWIRE / November 21, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that the company has not yet been provided with ...